Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Capital Expenditures: 2022-2025

Historic Capital Expenditures for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $77,000.

  • Taysha Gene Therapies' Capital Expenditures rose 211.59% to $77,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $486,000, marking a year-over-year increase of 23.66%. This contributed to the annual value of $374,000 for FY2024, which is 90.33% down from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Capital Expenditures is $77,000, which was down 80.15% from $388,000 recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Capital Expenditures peaked at $8.4 million during Q1 2022, and registered a low of -$69,000 during Q3 2024.
  • Its 3-year average for Capital Expenditures is $473,100, with a median of $50,000 in 2025.
  • Examining YoY changes over the last 5 years, Taysha Gene Therapies' Capital Expenditures showed a top increase of 735.42% in 2024 and a maximum decrease of 111.76% in 2024.
  • Taysha Gene Therapies' Capital Expenditures (Quarterly) stood at $2.3 million in 2022, then crashed by 99.26% to $17,000 in 2023, then plummeted by 111.76% to -$2,000 in 2024, then soared by 211.59% to $77,000 in 2025.
  • Its Capital Expenditures was $77,000 in Q3 2025, compared to $388,000 in Q2 2025 and $23,000 in Q1 2025.